301 related articles for article (PubMed ID: 26959889)
1. Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Shamanna RA; Lu H; Croteau DL; Arora A; Agarwal D; Ball G; Aleskandarany MA; Ellis IO; Pommier Y; Madhusudan S; Bohr VA
Oncotarget; 2016 Mar; 7(12):13269-84. PubMed ID: 26959889
[TBL] [Abstract][Full Text] [Related]
2. MIB1-mediated degradation of WRN promotes cellular senescence in response to camptothecin treatment.
Li M; Liu B; Yi J; Yang Y; Wang J; Zhu WG; Luo J
FASEB J; 2020 Sep; 34(9):11488-11497. PubMed ID: 32652764
[TBL] [Abstract][Full Text] [Related]
3. Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease.
Bird JL; Jennert-Burston KC; Bachler MA; Mason PA; Lowe JE; Heo SJ; Campisi J; Faragher RG; Cox LS
Biogerontology; 2012 Feb; 13(1):49-62. PubMed ID: 21786128
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
5. WRN counteracts the NHEJ pathway upon camptothecin exposure.
Otsuki M; Seki M; Kawabe Y; Inoue E; Dong YP; Abe T; Kato G; Yoshimura A; Tada S; Enomoto T
Biochem Biophys Res Commun; 2007 Apr; 355(2):477-82. PubMed ID: 17303082
[TBL] [Abstract][Full Text] [Related]
6. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
7. Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase.
Futami K; Takagi M; Shimamoto A; Sugimoto M; Furuichi Y
Biol Pharm Bull; 2007 Oct; 30(10):1958-61. PubMed ID: 17917271
[TBL] [Abstract][Full Text] [Related]
8. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
9. Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells.
Masuda K; Banno K; Yanokura M; Tsuji K; Kobayashi Y; Kisu I; Ueki A; Yamagami W; Nomura H; Tominaga E; Susumu N; Aoki D
Oncol Rep; 2012 Oct; 28(4):1146-52. PubMed ID: 22797812
[TBL] [Abstract][Full Text] [Related]
10. Werner protein stimulates topoisomerase I DNA relaxation activity.
Laine JP; Opresko PL; Indig FE; Harrigan JA; von Kobbe C; Bohr VA
Cancer Res; 2003 Nov; 63(21):7136-46. PubMed ID: 14612507
[TBL] [Abstract][Full Text] [Related]
11. Werner syndrome protein prevents DNA breaks upon chromatin structure alteration.
Turaga RV; Massip L; Chavez A; Johnson FB; Lebel M
Aging Cell; 2007 Aug; 6(4):471-81. PubMed ID: 17521388
[TBL] [Abstract][Full Text] [Related]
12. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
13. Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Sharma NK; Kumar A; Kumari A; Tokar EJ; Waalkes MP; Bortner CD; Williams J; Ehrenshaft M; Mason RP; Sinha BK
PLoS One; 2015; 10(11):e0141897. PubMed ID: 26540186
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells.
Gupta M; Fan S; Zhan Q; Kohn KW; O'Connor PM; Pommier Y
Clin Cancer Res; 1997 Sep; 3(9):1653-60. PubMed ID: 9815856
[TBL] [Abstract][Full Text] [Related]
16. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Sorensen M; Sehested M; Christensen IJ; Larsen JK; Jensen PB
Br J Cancer; 1998 Jun; 77(12):2152-61. PubMed ID: 9649127
[TBL] [Abstract][Full Text] [Related]
17. Human RecQ Helicases in DNA Double-Strand Break Repair.
Lu H; Davis AJ
Front Cell Dev Biol; 2021; 9():640755. PubMed ID: 33718381
[TBL] [Abstract][Full Text] [Related]
18. The Caenorhabditis elegans Werner syndrome protein participates in DNA damage checkpoint and DNA repair in response to CPT-induced double-strand breaks.
Hyun M; Choi S; Stevnsner T; Ahn B
Cell Signal; 2016 Mar; 28(3):214-223. PubMed ID: 26691982
[TBL] [Abstract][Full Text] [Related]
19. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
Liu W; Zhang R
Int J Oncol; 1998 Apr; 12(4):793-804. PubMed ID: 9499438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
